Summary & Overview

HCPCS J2281: Moxifloxacin Injection, 100 mg (Fresenius Kabi)

HCPCS Level II code J2281 denotes a 100 mg injection of moxifloxacin (Fresenius Kabi) that is explicitly listed as not therapeutically equivalent to J2280. This code identifies a specific injectable antibiotic product used in facility settings for systemic antimicrobial therapy. Nationally, product-specific J-codes matter for hospital billing, payer coverage policies, and inventory and formulary management because they distinguish between clinically and contractually non-interchangeable formulations.

Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise framing of clinical context and service settings, plus what to expect from payer coverage patterns and benchmarking content. The publication outlines common billing practice implications: product-specific coding, site-of-service considerations for infusion or inpatient administration, and implications for prior authorization and medical necessity review by major payers.

This summary prepares readers for detailed sections presenting benchmark pricing, coverage trends, and policy updates where available, as well as coding guidance tied to service lines and typical sites of administration. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ2281HCPCS Level IImoxifloxacininjectable antibioticinfusionhospital outpatientinpatientdrug J-codepharmacy billing

Billing Code Overview

HCPCS Level II code J2281 describes an injectable formulation of moxifloxacin (Fresenius Kabi), 100 mg, identified as not therapeutically equivalent to J2280. The code denotes a single-dose injectable antibiotic preparation of moxifloxacin for systemic use.

Service type: Injectable antimicrobial therapy

Typical site of service: Hospital inpatient, hospital outpatient department, or other facility-based infusion/administration settings

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 68-year-old male with community-acquired bacterial pneumonia is admitted to an inpatient medicine service. He is allergic to beta-lactam antibiotics and requires an intravenous fluoroquinolone. The physician orders intravenous moxifloxacin, supplied as J2281 (injection, moxifloxacin (Fresenius Kabi), 100 mg). The medication is prepared by pharmacy and administered via peripheral IV or existing central line by a registered nurse in the acute care setting. Documentation includes indication, dose (e.g., 400 mg IV once daily), route, lot number and expiration for controlled substance tracking if applicable, start/stop times, and any infusion-related reactions. Nursing documents vitals before and after administration and the medication administration record. Pharmacy documents acquisition cost and unit of measure for billing. Billing uses J2281 with appropriate units to reflect total milligrams administered and may append clinically appropriate modifiers to indicate circumstances such as service distinctiveness, discontinued administration, or drug wastage tracking.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/not administered to any patient	When part of an opened vial of `J2281` is discarded and the discarded amount must be reported for wastage billing per payor rules.
`JZ`	Entire drug/biological administered as billed	When the full vial/unit of `J2281` is administered with no wastage.
`22`	Increased procedural services	For significant additional work related to drug preparation or monitoring beyond usual for IV antibiotic administration (rare for `J2281`).
`23`	Unusual anesthesia	Not typically used for `J2281`, but present in list — reserved for rare instances when anesthesia is required for drug administration.
`52`	Reduced services	When administration is partially performed or less than the full service expected (e.g., abbreviated infusion).
`53`	Discontinued procedure	When `J2281` administration is started but stopped due to adverse reaction or other immediate contraindication.
`62`	Two surgeons	Not commonly used for drug administration; reserved if two providers share primary responsibility in a procedure setting involving the drug.
`78`	Return to operating room	Not standard for `J2281`; used when drug administration is directly related to an unexpected return to OR.
`80`	Assistant surgeon	Uncommon for medication billing; included only if an assistant surgeon billed in an operative context where the drug was administered.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare	When a qualified non-physician practitioner administers the drug under Medicare rules and billing requires this modifier.

Taxonomy Code	Specialty	Notes
`207RC0000X`	Internal Medicine	Hospitalists and internists commonly order and manage IV antibiotics such as `J2281`.
`207RH0000X`	Emergency Medicine	ED physicians initiate IV moxifloxacin for acute infections when indicated.
`207RR0500X`	Infectious Disease	ID specialists provide consultation on antibiotic selection and stewardship for `J2281` use.
`363LF0000X`	Pharmacy	Clinical pharmacists oversee preparation, dosing, and stewardship of IV moxifloxacin.
`208D00000X`	General Practice	Primary care physicians may order outpatient IV therapy in certain infusion clinic settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J18.9`	Pneumonia, unspecified organism	Common indication for IV moxifloxacin when pneumonia etiology requires fluoroquinolone therapy.
`J15.9`	Bacterial pneumonia, unspecified	Bacterial pneumonias sensitive to moxifloxacin may be treated inpatient with `J2281`.
`A41.9`	Sepsis, unspecified organism	Systemic infections where broad-spectrum IV antibiotics, including moxifloxacin, are considered.
`N39.0`	Urinary tract infection, site not specified	Complicated urinary tract infections sometimes treated with IV fluoroquinolones.
`K35.80`	Acute appendicitis without perforation or gangrene	Postoperative or complicated intra-abdominal infections may prompt IV antibiotic use including moxifloxacin.
`L03.90`	Cellulitis, unspecified	Skin and soft tissue infections where IV antibiotics are required and fluoroquinolones are an option in select patients.
`J44.1`	Chronic obstructive pulmonary disease with (acute) exacerbation	COPD exacerbations with suspected bacterial infection may lead to IV antibiotic administration.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when IV moxifloxacin is administered as an initial therapeutic infusion in an infusion center or outpatient setting.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Billed when the infusion of `J2281` requires additional monitored infusion time beyond the first hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if moxifloxacin is given via IM route, though `J2281` is typically IV.
`96374`	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug	Applied when moxifloxacin is administered by IV push rather than infusion.
`36415`	Collection of venous blood by venipuncture	Often performed before or during IV antibiotic therapy for cultures and labs guiding therapy with `J2281`.
`96361`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initiation of a new drug/biologic, with subsequent administration	Used when a new IV antimicrobial regimen including `J2281` is started and requires separate initiation billing.